|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15331534153515361537153815391540154115421543...15771578» |
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial initiation date: NCI-2013-00701: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=24, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Aug 2009 --> Feb 2009
- temozolomide / Generic mfg.
Trial primary completion date: Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=10, Recruiting, Sponsor: Mayo Clinic
Initiation date: Aug 2009 --> Feb 2009 Trial primary completion date: Dec 2015 --> Nov 2016
- Xofigo (radium Ra-223 dichloride) / Bayer
Trial primary completion date: Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=15, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Nov 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- Trial primary completion date, HEOR: Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=48, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Oct 2016 --> Oct 2017 Trial primary completion date: Sep 2014 --> Jul 2015
- Trial primary completion date: Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=60, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Sep 2014 --> Jul 2015 Trial primary completion date: Sep 2013 --> Sep 2015
- methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
Trial primary completion date: Sep 2013 --> Sep 2015 Trial primary completion date: Nov 2014 --> Nov 2015
- cyclophosphamide / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date, Post-transplantation: Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (clinicaltrials.gov) - Jun 11, 2015
P0, N=12, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Feb 2015 --> Feb 2017
- Campath (alemtuzumab) / Sanofi
Trial primary completion date: A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas (clinicaltrials.gov) - Jun 11, 2015
P1, N=24, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Feb 2015 --> Feb 2017 Trial primary completion date: Dec 2015 --> Jul 2016
- || Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Metastases: A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=90, Recruiting, Sponsor: Medical University of South Carolina
Trial primary completion date: Dec 2015 --> Jul 2016 Trial primary completion date: Nov 2014 --> Nov 2016
- sorafenib / Generic mfg.
Trial primary completion date: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Nov 2016 Trial primary completion date: Dec 2013 --> Jun 2014
- Tab-cel (tabelecleucel) / Atara, Pierre Fabre
Trial primary completion date: Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies (clinicaltrials.gov) - Jun 11, 2015
P2, N=112, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Dec 2013 --> Jun 2014 Trial primary completion date: Dec 2015 --> Dec 2016
- Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Trial primary completion date: Fosaprepitant in Patients Receiving Ifosfamide-based Regimen (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=47, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: May 2016 --> Mar 2015
- || Mekinist (trametinib) / Novartis, BeiGene, Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Combination therapy, Metastases: Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=111, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: May 2016 --> Mar 2015 Trial primary completion date: May 2015 --> Dec 2015
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Jun 11, 2015
P1, N=36, Recruiting, Sponsor: Pravin Kaumaya
Trial primary completion date: May 2015 --> Dec 2015 Trial primary completion date: Jan 2015 --> Jan 2016
- Sutent (sunitinib) / Pfizer
Trial primary completion date: Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy (clinicaltrials.gov) - Jun 11, 2015
P1, N=18, Recruiting, Sponsor: Centre Leon Berard
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Mar 2015 --> May 2016
- Trial primary completion date, Metastases: Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy (clinicaltrials.gov) - Jun 11, 2015
P3, N=300, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2015 --> May 2016 Trial primary completion date: Oct 2015 --> Oct 2016
- || Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: Axi-STS: A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas (clinicaltrials.gov) - Jun 11, 2015
P2, N=152, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Sep 2012 --> Jun 2016
- perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=92, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2012 --> Jun 2016 Trial primary completion date: Jun 2015 --> Oct 2015
- || Trial primary completion date: Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=750, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2015 --> Oct 2015 Trial primary completion date: Aug 2015 --> Aug 2016
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=22, Active, not recruiting, Sponsor: University of Oklahoma
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: Jul 2015 --> May 2016
- sunitinib / Generic mfg.
Trial primary completion date, Metastases: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2015 --> May 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- methotrexate IV / Generic mfg.
Trial termination, Trial primary completion date, Adverse events: Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays? (clinicaltrials.gov) - Jun 11, 2015
P2, N=34, Terminated, Sponsor: University College, London
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jun 2015; Recruitment almost complete, has been slow and challenging
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination, Trial primary completion date, Surgery: Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Jun 11, 2015
P2, N=100, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Jun 2015; Recruitment almost complete, has been slow and challenging Active, not recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2006
- Trial suspension: 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Suspended, Sponsor: Stanford University
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Dec 2006 Recruiting --> Suspended
- H1299 cell lysate with iscomatrix adjuvant vaccine / National Cancer Institute
Trial suspension, IO biomarker: Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Suspended
- || Hepacid (pegargiminase) / Polaris Pharma
Enrollment change: Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (clinicaltrials.gov) - Jun 11, 2015
P1, N=88, Recruiting, Sponsor: Polaris Group
Recruiting --> Suspended N=47 --> 88
- Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date, Oncolytic virus, Metastases: New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=0, Withdrawn, Sponsor: Hadassah Medical Organization
N=47 --> 88 N=30 --> 0 | Initiation date: Sep 2010 --> Jul 2011 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2013 --> Jul 2011
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=1200, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
N=30 --> 0 | Initiation date: Sep 2010 --> Jul 2011 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2013 --> Jul 2011 N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017
- | Enrollment open, Enrollment change, Metastases: Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy (clinicaltrials.gov) - Jun 11, 2015
P3, N=300, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=800 --> 1200 | Trial primary completion date: Sep 2015 --> Sep 2017 Suspended --> Recruiting | N=200 --> 300
- celecoxib oral / Generic mfg.
Enrollment change, Trial suspension, Tumor cell: Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas (clinicaltrials.gov) - Jun 10, 2015
P1, N=38, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting | N=200 --> 300 N=120 --> 38 | Recruiting --> Suspended
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment open, Metastases: BGB-A317_Study_001: Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors (clinicaltrials.gov) - Jun 10, 2015
P1, N=64, Recruiting, Sponsor: BeiGene
N=120 --> 38 | Recruiting --> Suspended Not yet recruiting --> Recruiting
- cisplatin / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis (clinicaltrials.gov) - Jun 10, 2015
P1, N=10, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=36 --> 10 | Trial primary completion date: May 2016 --> May 2015
- carboplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Surgery: Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer (clinicaltrials.gov) - Jun 6, 2015
P1, N=12, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting | N=36 --> 10 | Trial primary completion date: May 2016 --> May 2015 N=20 --> 12
- New P1 trial, Surgery: Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery (clinicaltrials.gov) - Jun 6, 2015
P1, N=21, Not yet recruiting, Sponsor: Blaze Bioscience Inc.
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases: Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus (clinicaltrials.gov) - Jun 3, 2015
P2, N=20, Completed, Sponsor: Gynecologic Oncology Group
N=20 --> 12 N=43 --> 20
- Torisel (temsirolimus) / Pfizer
Enrollment change: Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jun 3, 2015
P1/2, N=115, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=43 --> 20 N=144 --> 115
- doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Chemotherapy-induced Symptoms in Sarcoma Patients and the Impact of Tumor Burden (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=11, Completed, Sponsor: University of Pittsburgh
N=144 --> 115 Active, not recruiting --> Completed | N=50 --> 11 | Trial primary completion date: Jun 2015 --> May 2014
- ||| Votrient (pazopanib) / Novartis, BeiGene, Sutent (sunitinib) / Pfizer
Enrollment closed, Trial primary completion date, Stroma, Metastases: PAGIST: Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (clinicaltrials.gov) - Jun 1, 2015
P2, N=72, Active, not recruiting, Sponsor: Scandinavian Sarcoma Group
Active, not recruiting --> Completed | N=50 --> 11 | Trial primary completion date: Jun 2015 --> May 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Jan 2015
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
New P1 trial: T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (clinicaltrials.gov) - May 29, 2015
P1, N=36, Recruiting, Sponsor: Shenzhen Second People's Hospital
- | Trial completion, Surgery: Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus (clinicaltrials.gov) - May 28, 2015
P3, N=2616, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Jan 2015 Active, not recruiting --> Completed
- | SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax, Roswell Park Comprehensive Cancer Center
New P2 trial: NCI-2015-00694: SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - May 28, 2015
P2, N=50, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, PD(L)-1 Biomarker, Metastases: Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov) - May 28, 2015
P2, N=37, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Sutent (sunitinib) / Pfizer
Trial completion, Enrollment change, Trial primary completion date, Metastases: SunRaSe: Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma (clinicaltrials.gov) - May 28, 2015
P1, N=9, Completed, Sponsor: Heidelberg University
Not yet recruiting --> Recruiting Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Feb 2013 --> Nov 2014
- | imatinib / Generic mfg.
Enrollment open: Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST (clinicaltrials.gov) - May 27, 2015
P3, N=300, Recruiting, Sponsor: Heikki Joensuu
Recruiting --> Completed | N=12 --> 9 | Trial primary completion date: Feb 2013 --> Nov 2014 Not yet recruiting --> Recruiting
- | Marqibo (vincristine liposomal) / Servier, Aurobindo
Trial completion, Enrollment change: To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer (clinicaltrials.gov) - May 27, 2015
P1/2, N=22, Completed, Sponsor: Spectrum Pharmaceuticals, Inc
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=60 --> 22
- | Imlygic (talimogene laherparepvec) / Amgen
New P1/2 trial, Metastases: TVEC and Preop Radiation for Sarcoma (4 ml Dose) (clinicaltrials.gov) - May 26, 2015
P1/2, N=32, Not yet recruiting, Sponsor: Milhem, Mohammed M
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015
P1b, N=78, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=60 --> 22 Active, not recruiting --> Completed | N=120 --> 78
- imatinib / Generic mfg.
Enrollment change: Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer (clinicaltrials.gov) - May 22, 2015
P2, N=26, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=120 --> 78 N=51 --> 26
- |||||||||| Lartruvo (olaratumab) / Eli Lilly
New P3 trial, Metastases: ANNOUNCE: A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 22, 2015
P3, N=460, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||||| lorvotuzumab mertansine (IMGN901) / AbbVie
New P2 trial: Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (clinicaltrials.gov) - May 22, 2015
P2, N=150, Not yet recruiting, Sponsor: Children's Oncology Group